Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

OWLT vs LMAT vs NVCR vs ATRC vs IRTC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OWLT
Owlet, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$17.66B
5Y Perf.-95.8%
LMAT
LeMaitre Vascular, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$2.46B
5Y Perf.+174.0%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-85.8%
ATRC
AtriCure, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$1.41B
5Y Perf.-39.6%
IRTC
iRhythm Technologies, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$4.10B
5Y Perf.-50.7%

OWLT vs LMAT vs NVCR vs ATRC vs IRTC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OWLT logoOWLT
LMAT logoLMAT
NVCR logoNVCR
ATRC logoATRC
IRTC logoIRTC
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Devices
Market Cap$17.66B$2.46B$1.92B$1.41B$4.10B
Revenue (TTM)$107M$256M$674M$552M$788M
Net Income (TTM)$-46M$62M$-173M$-5M$-28M
Gross Margin50.8%72.4%75.2%75.5%71.0%
Operating Margin-10.5%28.5%-27.2%-0.4%-3.3%
Forward P/E36.1x428.7x27422.7x
Total Debt$13M$186M$290M$88M$731M
Cash & Equiv.$36M$28M$103M$167M$236M

OWLT vs LMAT vs NVCR vs ATRC vs IRTCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OWLT
LMAT
NVCR
ATRC
IRTC
StockNov 20May 26Return
Owlet, Inc. (OWLT)1004.2-95.8%
LeMaitre Vascular, … (LMAT)100274.0+174.0%
NovoCure Limited (NVCR)10014.2-85.8%
AtriCure, Inc. (ATRC)10060.4-39.6%
iRhythm Technologie… (IRTC)10049.3-50.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: OWLT vs LMAT vs NVCR vs ATRC vs IRTC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LMAT leads in 6 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Owlet, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
OWLT
Owlet, Inc.
The Growth Leader

OWLT is the #2 pick in this set and the best alternative if growth is your priority.

  • 35.4% revenue growth vs NVCR's 8.3%
Best for: growth
LMAT
LeMaitre Vascular, Inc.
The Income Pick

LMAT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 15 yrs, beta 0.57, yield 0.7%
  • 6.1% 10Y total return vs IRTC's 379.3%
  • Lower volatility, beta 0.57, Low D/E 47.2%, current ratio 12.89x
  • Beta 0.57, yield 0.7%, current ratio 12.89x
Best for: income & stability and long-term compounding
NVCR
NovoCure Limited
The Healthcare Pick

NVCR plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
ATRC
AtriCure, Inc.
The Healthcare Pick

ATRC lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
IRTC
iRhythm Technologies, Inc.
The Growth Play

IRTC is the clearest fit if your priority is growth exposure.

  • Rev growth 26.2%, EPS growth 61.7%, 3Y rev CAGR 22.1%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthOWLT logoOWLT35.4% revenue growth vs NVCR's 8.3%
ValueLMAT logoLMATLower P/E (36.1x vs 27422.7x)
Quality / MarginsLMAT logoLMAT24.3% margin vs OWLT's -42.5%
Stability / SafetyLMAT logoLMATBeta 0.57 vs NVCR's 2.20, lower leverage
DividendsLMAT logoLMAT0.7% yield; 15-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)LMAT logoLMAT+33.3% vs IRTC's -8.3%
Efficiency (ROA)LMAT logoLMAT10.3% ROA vs OWLT's -58.6%, ROIC 9.7% vs -48.1%

OWLT vs LMAT vs NVCR vs ATRC vs IRTC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

OWLTOwlet, Inc.

Segment breakdown not available.

LMATLeMaitre Vascular, Inc.

Segment breakdown not available.

NVCRNovoCure Limited

Segment breakdown not available.

ATRCAtriCure, Inc.
FY 2025
Shipping and Handling
100.0%$2M
IRTCiRhythm Technologies, Inc.
FY 2025
Commercial Payors
52.5%$392M
Centers For Medicare And Medicaid
24.0%$179M
Healthcare Institutions
16.8%$126M
Non-contracted Third-party Payors
6.7%$50M

OWLT vs LMAT vs NVCR vs ATRC vs IRTC — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLMATLAGGINGIRTC

Income & Cash Flow (Last 12 Months)

LMAT leads this category, winning 3 of 6 comparable metrics.

IRTC is the larger business by revenue, generating $788M annually — 7.4x OWLT's $107M. LMAT is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to OWLT's -42.5%. On growth, IRTC holds the edge at +25.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.IRTC logoIRTCiRhythm Technolog…
RevenueTrailing 12 months$107M$256M$674M$552M$788M
EBITDAEarnings before interest/tax-$11M$81M-$165M$13M-$6M
Net IncomeAfter-tax profit-$46M$62M-$173M-$5M-$28M
Free Cash FlowCash after capex-$10M$79M-$48M$54M$19M
Gross MarginGross profit ÷ Revenue+50.8%+72.4%+75.2%+75.5%+71.0%
Operating MarginEBIT ÷ Revenue-10.5%+28.5%-27.2%-0.4%-3.3%
Net MarginNet income ÷ Revenue-42.5%+24.3%-25.7%-0.8%-3.5%
FCF MarginFCF ÷ Revenue-9.7%+30.9%-7.1%+9.7%+2.4%
Rev. Growth (YoY)Latest quarter vs prior year+6.6%+11.2%+12.3%+14.3%+25.7%
EPS Growth (YoY)Latest quarter vs prior year-3.3%+41.7%-100.0%+101.6%+55.7%
LMAT leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

ATRC leads this category, winning 4 of 6 comparable metrics.

On an enterprise value basis, LMAT's 33.4x EV/EBITDA is more attractive than ATRC's 77.7x.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.IRTC logoIRTCiRhythm Technolog…
Market CapShares × price$17.7B$2.5B$1.9B$1.4B$4.1B
Enterprise ValueMkt cap + debt − cash$17.6B$2.6B$2.1B$1.3B$4.6B
Trailing P/EPrice ÷ TTM EPS-2.17x42.82x-13.80x-115.83x-89.83x
Forward P/EPrice ÷ next-FY EPS est.36.14x428.71x27422.73x
PEG RatioP/E ÷ EPS growth rate2.21x
EV / EBITDAEnterprise value multiple33.39x77.75x
Price / SalesMarket cap ÷ Revenue167.06x9.85x2.92x2.63x5.49x
Price / BookPrice ÷ Book value/share77.22x6.29x5.51x2.70x26.16x
Price / FCFMarket cap ÷ FCF33.01x29.15x118.84x
ATRC leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

LMAT leads this category, winning 6 of 9 comparable metrics.

LMAT delivers a 16.2% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-6 for OWLT. ATRC carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRTC's 4.79x. On the Piotroski fundamental quality scale (0–9), LMAT scores 7/9 vs OWLT's 4/9, reflecting strong financial health.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.IRTC logoIRTCiRhythm Technolog…
ROE (TTM)Return on equity-5.9%+16.2%-50.8%-1.0%-20.6%
ROA (TTM)Return on assets-58.6%+10.3%-16.5%-0.7%-2.8%
ROICReturn on invested capital-48.1%+9.7%-16.4%-0.6%-5.2%
ROCEReturn on capital employed-30.5%+12.3%-28.9%-0.6%-4.4%
Piotroski ScoreFundamental quality 0–947556
Debt / EquityFinancial leverage0.37x0.47x0.85x0.18x4.79x
Net DebtTotal debt minus cash-$22M$157M$187M-$79M$495M
Cash & Equiv.Liquid assets$36M$28M$103M$167M$236M
Total DebtShort + long-term debt$13M$186M$290M$88M$731M
Interest CoverageEBIT ÷ Interest expense-7.21x24.99x-96.80x0.47x-1.48x
LMAT leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LMAT leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in LMAT five years ago would be worth $21,818 today (with dividends reinvested), compared to $348 for OWLT. Over the past 12 months, LMAT leads with a +33.3% total return vs IRTC's -8.3%. The 3-year compound annual growth rate (CAGR) favors LMAT at 18.2% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.IRTC logoIRTCiRhythm Technolog…
YTD ReturnYear-to-date-69.9%+34.9%+28.3%-29.2%-28.7%
1-Year ReturnPast 12 months+17.4%+33.3%+1.1%-8.3%-8.3%
3-Year ReturnCumulative with dividends+4.2%+65.2%-75.7%-41.8%-2.1%
5-Year ReturnCumulative with dividends-96.5%+118.2%-91.3%-64.2%+56.1%
10-Year ReturnCumulative with dividends-96.4%+608.6%+30.3%+95.1%+379.3%
CAGR (3Y)Annualised 3-year return+1.4%+18.2%-37.6%-16.5%-0.7%
LMAT leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

LMAT leads this category, winning 2 of 2 comparable metrics.

LMAT is the less volatile stock with a 0.57 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LMAT currently trades 91.4% from its 52-week high vs OWLT's 28.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.IRTC logoIRTCiRhythm Technolog…
Beta (5Y)Sensitivity to S&P 5002.16x0.71x2.15x0.95x0.73x
52-Week HighHighest price in past year$16.94$118.12$20.06$43.18$212.00
52-Week LowLowest price in past year$3.99$78.35$9.82$26.62$112.31
% of 52W HighCurrent price vs 52-week peak+28.7%+91.4%+83.9%+64.4%+58.9%
RSI (14)Momentum oscillator 0–10043.848.369.845.044.1
Avg Volume (50D)Average daily shares traded341K244K1.5M669K524K
LMAT leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: OWLT as "Buy", LMAT as "Buy", NVCR as "Buy", ATRC as "Buy", IRTC as "Buy". Consensus price targets imply 311.5% upside for OWLT (target: $20) vs 8.1% for LMAT (target: $117). LMAT is the only dividend payer here at 0.73% yield — a key consideration for income-focused portfolios.

MetricOWLT logoOWLTOwlet, Inc.LMAT logoLMATLeMaitre Vascular…NVCR logoNVCRNovoCure LimitedATRC logoATRCAtriCure, Inc.IRTC logoIRTCiRhythm Technolog…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$20.00$116.67$33.50$51.33$193.67
# AnalystsCovering analysts520151919
Dividend YieldAnnual dividend ÷ price+0.7%
Dividend StreakConsecutive years of raises15
Dividend / ShareAnnual DPS$0.79
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+0.8%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

LMAT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ATRC leads in 1 (Valuation Metrics).

Best OverallLeMaitre Vascular, Inc. (LMAT)Leads 4 of 6 categories
Loading custom metrics...

OWLT vs LMAT vs NVCR vs ATRC vs IRTC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is OWLT or LMAT or NVCR or ATRC or IRTC a better buy right now?

For growth investors, Owlet, Inc.

(OWLT) is the stronger pick with 35. 4% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). LeMaitre Vascular, Inc. (LMAT) offers the better valuation at 42. 8x trailing P/E (36. 1x forward), making it the more compelling value choice. Analysts rate Owlet, Inc. (OWLT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — OWLT or LMAT or NVCR or ATRC or IRTC?

On forward P/E, LeMaitre Vascular, Inc.

is actually cheaper at 36. 1x.

03

Which is the better long-term investment — OWLT or LMAT or NVCR or ATRC or IRTC?

Over the past 5 years, LeMaitre Vascular, Inc.

(LMAT) delivered a total return of +118. 2%, compared to -96. 5% for Owlet, Inc. (OWLT). Over 10 years, the gap is even starker: LMAT returned +608. 8% versus OWLT's -95. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — OWLT or LMAT or NVCR or ATRC or IRTC?

By beta (market sensitivity over 5 years), LeMaitre Vascular, Inc.

(LMAT) is the lower-risk stock at 0. 71β versus Owlet, Inc. 's 2. 16β — meaning OWLT is approximately 205% more volatile than LMAT relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 5% for iRhythm Technologies, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — OWLT or LMAT or NVCR or ATRC or IRTC?

By revenue growth (latest reported year), Owlet, Inc.

(OWLT) is pulling ahead at 35. 4% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -169. 9% for Owlet, Inc.. Over a 3-year CAGR, IRTC leads at 22. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — OWLT or LMAT or NVCR or ATRC or IRTC?

LeMaitre Vascular, Inc.

(LMAT) is the more profitable company, earning 23. 1% net margin versus -39. 6% for Owlet, Inc. — meaning it keeps 23. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LMAT leads at 27. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is OWLT or LMAT or NVCR or ATRC or IRTC more undervalued right now?

On forward earnings alone, LeMaitre Vascular, Inc.

(LMAT) trades at 36. 1x forward P/E versus 27422. 7x for iRhythm Technologies, Inc. — 27386. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OWLT: 311. 5% to $20. 00.

08

Which pays a better dividend — OWLT or LMAT or NVCR or ATRC or IRTC?

In this comparison, LMAT (0.

7% yield) pays a dividend. OWLT, NVCR, ATRC, IRTC do not pay a meaningful dividend and should not be held primarily for income.

09

Is OWLT or LMAT or NVCR or ATRC or IRTC better for a retirement portfolio?

For long-horizon retirement investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), 0. 7% yield, +608. 8% 10Y return). Owlet, Inc. (OWLT) carries a higher beta of 2. 16 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LMAT: +608. 8%, OWLT: -95. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between OWLT and LMAT and NVCR and ATRC and IRTC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OWLT is a mid-cap high-growth stock; LMAT is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; IRTC is a small-cap high-growth stock. LMAT pays a dividend while OWLT, NVCR, ATRC, IRTC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

OWLT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 30%
Run This Screen
Stocks Like

LMAT

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 14%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

ATRC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Gross Margin > 45%
Run This Screen
Stocks Like

IRTC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 12%
  • Gross Margin > 42%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform OWLT and LMAT and NVCR and ATRC and IRTC on the metrics below

Revenue Growth>
%
(OWLT: 6.6% · LMAT: 11.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.